NEW YORK (GenomeWeb News) – Illumina and Genpathway have partnered to offer scientists a solution for studying transcription factor binding and gene regulation in drug development research, Illumina said today.
Under the partnership, Genpathway will prepare samples using its FactorPath ChIP assays and will conduct data analysis using its software. The sequencing will be handled by Illumina’s Sequencing Services, which will employ the firm’s high-throughput Genome Analyzer, the company said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.